Osteotech specialises in biologic products for regenerative healing which will align with Medtronic’s current range of bone generating and biologic therapies used by surgeons.
“The acquisition complements our bone healing portfolio and will expand our current presence in spine, orthopedic trauma and dental into new treatment areas including joint reconstruction, foot and ankle, sports medicine and neurosurgery,” commented Tom McGuinness, general manager of Medtronic’s Biologics business.
“It will expand our reach into other musculoskeletal therapies and will accelerate our innovation and progress,” he added.